BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Sepracor, Inc. (SEPR): BROVANA™ Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference


10/25/2007 1:34:35 PM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that it presented safety and efficacy data from several studies of BROVANA™ (arformoterol tartrate) Inhalation Solution at CHEST 2007, the annual meeting of the American College of Chest Physicians, in Chicago. The Effect of Twice-Daily Nebulized Arformoterol on QTC in Subjects With COPD This four-week, placebo-controlled, randomized, double-blind, multicenter, parallel-group, dose-ranging study evaluated changes in QTc interval in patients with chronic obstructive pulmonary disease (COPD) who were administered arformoterol at various doses, or placebo. Patients were divided into Part A (n=215) and were administered arformoterol 5 mcg, 15 mcg, or 25 mcg or placebo twice daily for two weeks, and subsequently re-randomized in Part B (n=191) and administered arformoterol 15 mcg, 25 mcg, or 50 mcg or placebo once daily for two weeks. Two models were used to calculate QTc from results of electrocardiograms (ECGs) for each of the patients in the study. Based on the data analyzed in this study, dosing with arformoterol did not prolong cardiac repolarization.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->